• Co-Diagnostics reported progress with joint venture CoSara on two Ebola PCR tests, including a pan-Ebola assay and a multiplex strain-differentiating assay.
• Work includes point-of-care workflow configurations for the Co-Dx PCR platform, aiming to support outbreak response in Central Africa.
• Development targets the first blood-based pathogen assay for the Co-Dx PCR Pro, expanding the platform beyond swab-based infectious disease testing.
• Programs remain in development, pending validation and regulatory review before any deployment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606020900PR_NEWS_USPR_____LA73568) on June 02, 2026, and is solely responsible for the information contained therein.